Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Via Nova Therapeutics

Request full access

Innovative therapies for acute and subacute viral infections, leveraging rapid diagnostics and telemedicine advancements

Berkeley, United StatesFounded 2020Biotech & Life Sciences

About Via Nova Therapeutics

Via Nova Therapeutics is a pioneering startup in the healthcare sector, specifically in the field of virology. Their primary objective is to develop innovative therapies for viral diseases, with a particular emphasis on acute and subacute infections. Unlike many in the industry who focus on chronic viral infections, Via Nova is carving a new path, hence their name which translates from Latin to 'New Road'.

Their business model is centered around the discovery and development of these novel therapies and then efficiently bringing them to clinical use. They are capitalizing on the advent of rapid at-home and point-of-care diagnostics for these infections, which they believe opens up new opportunities to bring their treatments to the clinic.

Their target market is broad, encompassing anyone suffering from acute and subacute viral infections, a segment they believe represents the next frontier of unmet medical need in virology. They generate revenue through the development and sale of these innovative therapies to healthcare providers.

In simpler terms, Via Nova Therapeutics is a company that is working to find new treatments for viral diseases that come on quickly and can be severe but are not long-lasting (acute) or those that are not as severe but last a long time (subacute). They are focusing on these types of infections because they believe there is a big need for new treatments in this area. They make money by creating these treatments and selling them to doctors and hospitals.

Source: Dealroom company data

At a glance

Status
Operational
Employees
2
Open positions
None listed
Dealroom signal
56.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2021 $20M $80M Aditum Bio —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Via Nova Therapeutics website traffic

Latest recorded traffic for Via Nova Therapeutics is 950 monthly website visits, down 52.5% over the last three months. Via Nova Therapeutics's team grew 0% over the past year.

Latest monthly visits950 3-month web change-52.5% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Harness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs Babraham, United Kingdom Operational 5 $35M $90M
Ziphius VaccinesAddresses urgent global public health needs by developing mRNA-based vaccines Ghent, Belgium Operational
KimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors Paris, France Operational
SideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers Paris, France Closed
AntegenesGenetic tests for personalized cancer risk prevention Tartu, Estonia Operational
Brenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system Clermont-Ferrand, France Operational
Akston BiosciencesLeverages its core expertise of designing novel fusion proteins to develop and manufacture new classes of biologic therapeutics for Type 1 diabetes (T1D) prevention, ultra-long acting insulin therapy, and vaccines Beverly, United States Operational
Exeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics Dijon, France Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Via Nova Therapeutics in the Berkeley ecosystem

Live from Dealroom

The Via Nova Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Aditum Bio

Other known investors1 additional known investor

  • QB3
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Berkeley HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Via Nova Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Via Nova Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.